| Ytd | -50.43% | |
| 1y | -68.72% |
| Open | 2.33 | Prev Close | 2.36 | Low | 2.28 | High | 2.37 | Mkt Cap | 1.22M |
| Vol | 34.28K | Avg Vol | 66.87K | EPS | -8.99 | P/E | -0.25 | Forward P/E | -0.24 |
| Beta | 0.40 | Short Ratio | 0.77 | Inst. Own | 3.57% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.81 | 200-d Avg | 4.01 | 1yr Est | 1.30 |
ACON News
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus E
PR Audio: BROOMFIELD, Colo., August 04, 2026 – PRISM MediaWire (Press Release Service – Press Releas
Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery an
PR Audio: Broomfield, CO, July 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Dis
141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. tran
PR Audio: BROOMFIELD, Colo., July 21, 2026 – PRISM MediaWire (Press Release Service – Press Release
Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understandin
PR Audio: BROOMFIELD, Colo., July 07, 2026 – PRISM MediaWire (Press Release Service – Press Release
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understandin
BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driv
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven p
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven p
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
PR Audio: BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release D
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”)
BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distributio
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Broomfield, CO, June 3, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution)
Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group Add
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a ro
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-s
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a ro
Top Wall Street analysts changed outlook on top names. For full changes, see analyst ratings page. S
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the
Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other
Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consens
Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Patent covers use of AI in workflows of future products to accelerate company's ability to scale
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and lowers the
Aclarion, Inc. (NASDAQ:ACON, ACONW))) ("Aclarion" or the "Company") today announced
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-s
Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan's non-invasi
Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance shee
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Aclarion Inc. (NASDAQ: ACON) provided a corporate update on Thursday, reporting strong commercial mo
ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Acce
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st